BridgeBio Pharma Inc Forecast, price target & analysts
BridgeBio Pharma Inc Target price 2025 - Analyst rating & recommendation
BridgeBio Pharma Inc Classifications & Recommendation:
BridgeBio Pharma Inc Price Target
| Target Price | $55.19 |
| Price | $33.87 |
| Potential |
62.94%
register free of charge
|
| Number of Estimates | 16 |
|
16 Analysts have issued a price target BridgeBio Pharma Inc 2026 .
The average BridgeBio Pharma Inc target price is $55.19.
This is
62.94%
register free of charge
$95.00
180.48%
register free of charge
$37.00
9.24%
register free of charge
|
|
| A rating was issued by 19 analysts: 16 Analysts recommend BridgeBio Pharma Inc to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the BridgeBio Pharma Inc stock has an average upside potential 2026 of
62.94%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 221.90 | 238.51 |
| 2,286.02% | 7.49% | |
| EBITDA Margin | -257.45% | -278.07% |
| 95.96% | 8.01% | |
| Net Margin | -246.65% | -311.99% |
| 96.94% | 26.49% |
17 Analysts have issued a sales forecast BridgeBio Pharma Inc 2025 . The average BridgeBio Pharma Inc sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an BridgeBio Pharma Inc EBITDA forecast 2025. The average BridgeBio Pharma Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 BridgeBio Pharma Inc Analysts have issued a net profit forecast 2025. The average BridgeBio Pharma Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.88 | -3.92 |
| 27.09% | 36.11% | |
| P/E | negative | |
| EV/Sales | 33.46 |
10 Analysts have issued a BridgeBio Pharma Inc forecast for earnings per share. The average BridgeBio Pharma Inc EPS is
This results in the following potential growth metrics and future valuations:
BridgeBio Pharma Inc...
Current BridgeBio Pharma Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 15 2025 |
| Redburn Atlantic |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Mar 24 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Feb 21 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Feb 21 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Feb 21 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 13 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 15 2025 |
|
Locked
Redburn Atlantic:
Locked
➜
Locked
|
Mar 31 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Mar 24 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Feb 21 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Feb 21 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Feb 21 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 13 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
